In hypertension management, examining the role of newer agents including aldosterone synthase inhibitors and injectable angiotensinogen inhibitors which are on the horizon and how the diffusion of such therapies may influence AF-related stroke and mortality is needed[193,194]. This evidence concerns the gene CYP11B2 and stroke disorder.